Duck Cho
성균관대학교 의과대학 · 의학
Duck Cho 교수의 연구실은 자연살해(NK) 세포 기반 면역치료의 임상적 응용을 목표로 하며, 특히 암 치료를 위한 효과적인 NK 세포 확대 기술 개발에 초점을 맞추고 있습니다. K562 세포를 유전자 수정하여 NK 세포의 강력한 증식을 유도하는 피더 세포 시스템을 개발했으며, IL-21과 같은 사이토카인과의 조합을 통해 활성화된 NK 세포를 대량으로 확보하는 데 성공했습니다. 이는 소견암, 림프성모세포성암 등 난치성 암에 대한 신규 치료 전략으로 이어지고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Among pediatric solid tumors, EWS and rhabdomyosarcoma are exquisitely sensitive to expanded NK cells. The NK expansion method described here has been adapted to large-scale conditions and supports a phase I clinical study including patients with these malignancies.
Natural killer (NK) cells can kill a wide range of cancer cells and are a promising tool for cell therapy of cancer. NK cells cytotoxicity is regulated by a balance between stimulatory and inhibitory signals. Interleukin-2 is known to increase NK cell cytotoxicity. Although many cytokines have been studied in efforts to induce durable NK cell expansions, most reports indicate a rather modest effect and the requirement for additional stimuli. We found that contact with the K562 myeloid leukemia c
<b>Background:</b> Natural Killer (NK) cell-based immunotherapy used to treat cancer requires the adoptive transfer of a large number of activated NK cells. Here, we report a new effective method to expand human NK cells <i>ex vivo</i> using K562 cells genetically engineered (GE) to express OX40 ligand (K562-OX40L) in combination with a short exposure to soluble IL-21. In addition, we describe a possible mechanism of the NK cell expansion through the OX40 receptor-OX40 ligand axis which is depen
U87 GBM cells with stemness features demonstrate increased cytotoxicity to NK cells in association with altered NKG2D ligand expression of NK cell activating receptor. Applying immune modulation to GBM treatment may be a promising adjuvant therapy in patients with intractable GBM.
The characterization of natural killer (NK) cells initially occurred in the 1970s and 1980s as a result of efforts by investigators such as Rolf Kiessling and Ronald Heberman. It was observed that a certain population of cells, freshly isolated from normal, unimmunized hosts, could lyse allogeneic tumor cells without sensitization. At the time, these cells were just considered to be a population of non-T, non-B lymphocytes. After the introduction of modern technologies such as monoclonal antibod
